Pharmaceuticals company Breckenridge Pharmaceutical Inc reported on Friday the receipt of approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Pomalidomide Capsules.
The company has partnered with Natco Pharma Limited for the development and manufacture of Pomalidomide Capsules (generic, Pomalyst). Pomalidomide is an anti-angiogenic and also acts as an immunomodulator.
Based on the industry sales data, Pomalyst had annual sales of USD957m during the 12 months ending September 2020.
In conjunction, Celgene, Breckenridge and Natco have settled the US district court litigation with respect to Pomalyst.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream